Risk Evaluation and Mitigation Strategy (REMS) Assessment Protocol - Zydelig (idelalisib) tablets (Zydelig REMS KAB) First published 10/11/2015 Last updated 02/07/2024 EU PAS number:EUPAS11551 Study Finalised